Hosted on MSN
INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results , with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ ...
Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation ...
Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after ...
Investors in Incyte Corporation (Symbol: INCY) saw new options become available this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
Incyte Corporation offers strong growth potential and a low valuation, driven by expanding margins and a robust earnings outlook. INCY's revenue is anchored by Jakafi, but a diverse pipeline and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results